1. A Review of Drug Therapy in Vestibular Schwannoma
- Author
-
Bin Wang, Junwei Ren, Xiang Yang Huang, Yu Zhang, Jianfei Long, and Ping Zhong
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Pharmaceutical Science ,Antineoplastic Agents ,Review ,Schwannoma ,therapeutic targets ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Ototoxicity ,Drug Discovery ,medicine ,Humans ,Pharmacology ,VEGFR inhibitor ,business.industry ,Therapeutic effect ,Neurotoxicity ,Neuroma, Acoustic ,medicine.disease ,drug therapy ,Clinical trial ,Radiation therapy ,Drug repositioning ,030104 developmental biology ,vestibular schwannomas ,030220 oncology & carcinogenesis ,business - Abstract
Vestibular schwannomas (VSs, also known as acoustic neuromas) are benign intracranial tumors commonly managed with observation, surgery, and radiotherapy. There is currently no approved pharmacotherapy for VS patients, which is why we conducted a detailed search of relevant literature from PubMed and Web of Science to explore recent advances and experiences in drug therapy. VSs feature a long course of disease that requires treatment to have minimal long-term side effects. Conventional chemotherapeutic agents are characterized by neurotoxicity or ototoxicity, poor effect on slow-growing tumors, and may induce new mutations in patients who have lost tumor suppressor function, and therefore are unsuitable for treating VSs. Along with the well-investigated molecular pathophysiology of VS and the increasingly accessible technology such as drug repositioning platform, many molecular targeted inhibitors have been identified and shown certain therapeutic effects in preclinical experiments or clinical trials.
- Published
- 2021
- Full Text
- View/download PDF